Download PDF
J Pediatr Genet 2016; 05(02): 098-104
DOI: 10.1055/s-0036-1579766
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis

Jesse Lee Kresak
1   Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, United States
,
Meggen Walsh
1   Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, United States
› Author Affiliations
Further Information

Publication History

10 July 2015

10 August 2015

Publication Date:
09 March 2016 (online)

Also available at
    Permissions and Reprints

Abstract

The neurofibromatoses are a heterogeneous group of hereditary cancer syndromes that lead to tumors of the central and peripheral nervous systems, as well as other organ systems. By far the most common form is neurofibromatosis 1 (96%), followed by neurofibromatosis 2 (3%), and a more recently recognized, lesser known form, schwannomatosis. The diagnostic criteria, pathogenesis, molecular considerations, and clinical manifestations are discussed in this review article.

Keywords

neurofibromatosis - NF1 - von Recklinghausen disease - NF2 - schwannomatosis
 

  • References

  • 1 DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105 (3 Pt 1) 608-614
    CrossrefPubMedGoogle Scholar
  • 2 Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13 (8) 834-843
    CrossrefPubMedGoogle Scholar
  • 3 Weiss S , et al. Enzinger and Weiss's Soft Tissue Tumors. Philadelphia, PA. Elsevier Saunders; 2014
    Google Scholar
  • 4 Brosius S. A history of von Recklinghausen's NF1. J Hist Neurosci 2010; 19 (4) 333-348
    CrossrefPubMedGoogle Scholar
  • 5 Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123 (1) 124-133
    CrossrefPubMedGoogle Scholar
  • 6 Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014; 18 (3) 297-306
    PubMedGoogle Scholar
  • 7 Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61 (1) 1-14 , quiz 15–16
    CrossrefPubMedGoogle Scholar
  • 8 Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 2007; 15 (2) 131-138
    CrossrefPubMedGoogle Scholar
  • 9 Rosai J , et al. Rosai and Ackerman's Surgical Pathology. 10th ed. Philadelphia, PA: Elsevier Saunders; 2011
    Google Scholar
  • 10 Robertson KA, Nalepa G, Yang FC , et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13 (12) 1218-1224
    CrossrefPubMedGoogle Scholar
  • 11 Crowe FW , et al. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL: Charles C Thomas; 1956
    Google Scholar
  • 12 Alper J, Holmes LB, Mihm Jr MC. Birthmarks with serious medical significance: nevocullular nevi, sebaceous nevi, and multiple café au lait spots. J Pediatr 1979; 95 (5 Pt 1): 696-700
    CrossrefPubMedGoogle Scholar
  • 13 Shimbashi T, Kamide R, Hashimoto T. Long-term follow-up in treatment of solar lentigo and café-au-lait macules with Q-switched ruby laser. Aesthetic Plast Surg 1997; 21 (6) 445-448
    CrossrefPubMedGoogle Scholar
  • 14 Yanoff M, Sassani J. Ocular Pathology. Philadelphia, PA: Elsevier Saunders; 2009
    Google Scholar
  • 15 Sharif S, Ferner R, Birch JM , et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24 (16) 2570-2575
    CrossrefPubMedGoogle Scholar
  • 16 Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004; 144 (5) 666-668
    CrossrefPubMedGoogle Scholar
  • 17 Tucker T, Schnabel C, Hartmann M , et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009; 46 (4) 259-265
    CrossrefPubMedGoogle Scholar
  • 18 Heervä E, Koffert A, Jokinen E , et al. A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 2012; 27 (11) 2333-2337
    CrossrefPubMedGoogle Scholar
  • 19 Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012; 5 (9) 852-862
    PubMedGoogle Scholar
  • 20 Evans DG, Huson SM, Donnai D , et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84 (304) 603-618
    PubMedGoogle Scholar
  • 21 Baser ME, Friedman JM, Aeschliman D , et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71 (4) 715-723
    CrossrefPubMedGoogle Scholar
  • 22 Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002; 59 (11) 1759-1765
    CrossrefPubMedGoogle Scholar
  • 23 Trofatter JA, MacCollin MM, Rutter JL , et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72 (5) 791-800
    CrossrefPubMedGoogle Scholar
  • 24 Rouleau GA, Merel P, Lutchman M , et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363 (6429) 515-521
    CrossrefPubMedGoogle Scholar
  • 25 Evans DG, Ramsden RT, Shenton A , et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007; 44 (7) 424-428
    CrossrefPubMedGoogle Scholar
  • 26 Love S, Perry A, Ironside J, Budka H. Greenfield's Neuropathology. 9th ed. Boca Raton, FL: CRC Press; 2015
    Google Scholar
  • 27 Selvanathan SK, Shenton A, Ferner R , et al. Further genotype—phenotype correlations in neurofibromatosis 2. Clin Genet 2010; 77 (2) 163-170
    CrossrefPubMedGoogle Scholar
  • 28 Smith MJ, Higgs JE, Bowers NL , et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011; 48 (4) 261-265
    CrossrefPubMedGoogle Scholar
  • 29 Stivaros SM, Stemmer-Rachamimov AO, Alston R , et al. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet 2015; 52 (8) 557-562
    CrossrefPubMedGoogle Scholar
  • 30 Dewan R, Pemov A, Kim HJ , et al. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro-oncol 2015; 17 (4) 566-573
    PubMedGoogle Scholar
  • 31 Maniakas A, Saliba I. Neurofibromatosis type 2 vestibular schwannoma treatment: a review of the literature, trends, and outcomes. Otol Neurotol 2014; 35 (5) 889-894
    CrossrefPubMedGoogle Scholar
  • 32 Neff BA, Wiet RM, Lasak JM , et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 2007; 117 (6) 1069-1072
    CrossrefPubMedGoogle Scholar
  • 33 Hamada Y, Iwaki T, Fukui M, Tateishi J. A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas. Surg Neurol 1997; 48 (4) 395-400
    CrossrefPubMedGoogle Scholar
  • 34 Plotkin SR, Merker VL, Halpin C , et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33 (6) 1046-1052
    CrossrefPubMedGoogle Scholar
  • 35 Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 2014; 73 (6) 1197-1204
    CrossrefPubMedGoogle Scholar
  • 36 Hilton DA, Hanemann CO. Schwannomas and their pathogenesis. Brain Pathol 2014; 24 (3) 205-220
    CrossrefPubMedGoogle Scholar
  • 37 Stemmer-Rachamimov AO, Ino Y, Lim ZY , et al. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 1998; 57 (12) 1164-1167
    CrossrefPubMedGoogle Scholar
  • 38 Berg JC, Scheithauer BW, Spinner RJ, Allen CM, Koutlas IG. Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. Hum Pathol 2008; 39 (5) 633-640
    CrossrefPubMedGoogle Scholar
  • 39 Hébert-Blouin MN, Amrami KK, Scheithauer BW, Spinner RJ. Multinodular/plexiform (multifascicular) schwannomas of major peripheral nerves: an underrecognized part of the spectrum of schwannomas. J Neurosurg 2010; 112 (2) 372-382
    CrossrefPubMedGoogle Scholar
  • 40 Bendon CL, Furniss D, Giele HP. Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study. J Plast Reconstr Aesthet Surg 2015; 68 (9) 1199-1203
    CrossrefPubMedGoogle Scholar
  • 41 Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81 (6) 496-499
    CrossrefPubMedGoogle Scholar
  • 42 Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011; 14 (4) 543-547
    CrossrefPubMedGoogle Scholar
  • 43 McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S. Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007; 125 (3) 389-394
    CrossrefPubMedGoogle Scholar
  • 44 Koontz NA, Wiens AL, Agarwal A, Hingtgen CM, Emerson RE, Mosier KM. Schwannomatosis: the overlooked neurofibromatosis?. AJR Am J Roentgenol 2013; 200 (6) W646-53
    Google Scholar
  • 45 MacCollin M, Chiocca EA, Evans DG , et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64 (11) 1838-1845
    CrossrefPubMedGoogle Scholar